Holen Sie sich die Stockscreener-App
48.27
0.00%
0.00
Handel nachbörslich:
48.27
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - TradingView
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - marketscreener.com
New Strong Buy Stocks for August 7th - The Globe and Mail
Best Value Stocks to Buy for August 7th - The Globe and Mail
Millennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock Titan
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Rx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and Media
Q2 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call High - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... - Yahoo! Finance Canada
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6%Here's Why - MarketBeat
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - Moomoo
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Navigating A 38% Potential Upside - DirectorsTalk Interviews
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) - morningstar.com
Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - Stock Titan
Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga
Supernus Pharmaceuticals Q2 Earnings Call Highlights - finance.yahoo.com
Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan
Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After Q2 Earni - GuruFocus
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement - Yahoo Finance
CNS-focused Supernus and Indivior agree merger terms - pharmaphorum.com
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates - Yahoo Finance
Supernus and Indivior agree to merge in all-stock deal - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9% - Yahoo Finance
Supernus Pharmaceuticals (SUPN) agrees merger-of-equals with Indivior and $1B special dividend - Stock Titan
Supernus and Indivior agree to merge in all-stock deal By Investing.com - Investing.com Nigeria
Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior | SUPN Stock News - Quiver Quantitative
Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, Vs. FactSet Est of $205.3M - Moomoo
BRIEF-Supernus Pharmaceuticals Q2 EPS USD -1.01 - TradingView
Press Release: Supernus Announces Second Quarter 2026 Financial Results - Moomoo
Press Release: Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader With Significant Scale - Moomoo
Why Supernus Pharmaceuticals Stock Topped the Market Today - The Globe and Mail
Supernus and Indivior to merge, forming $2.2B CNS drug company - Dealroom
1.61%
1.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):